Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
- 6 November 2003
- journal article
- Published by Springer Nature in Leukemia
- Vol. 18 (1) , 165-166
- https://doi.org/10.1038/sj.leu.2403186
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Possible regulation of Wilms’ tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA‐1 in human acute myeloid leukaemiasBritish Journal of Haematology, 2003
- WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapiesLeukemia, 2003
- Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptidesInternational Journal of Cancer, 2003
- Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsLeukemia, 2002
- CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemiaBlood, 2002
- Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 ProductThe Journal of Immunology, 2000
- Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene ( WT1 ) productImmunogenetics, 2000